Polaryx Therapeutics, Inc.

Polaryx Therapeutics, Inc. is a clinical-stage biotechnology company that discovers and develops treatments for rare pediatric lysosomal storage disorders. Its therapeutic pipeline comprises oral small molecule candidates and gene therapies targeting underlying cellular dysfunction and neuroinflammation. The company's lead product candidate is PLX-200, a reformulated oral solution targeting neuronal ceroid lipofuscinosis subtypes CLN2 and CLN3, Krabbe disease, and Sandhoff disease. Other programs include PLX-300, a small molecule in preclinical evaluation, PLX-100, an oral combination therapy, and PLX-400, an early-stage gene therapy. The company operates in the lysosomal storage disorders segment, developing therapies primarily for pediatric patients diagnosed with fatal genetic metabolic conditions.

The company maintains its principal executive offices in Paramus, New Jersey, and operates as a Nevada corporation. Polaryx utilizes external partnerships and receives consulting support across development functions from a team of eleven specialists based at its controlling shareholder in Hong Kong.

Summary of the business section of Polaryx Therapeutics's latest annual report, written by StockData.